Desflurane
| Desflurane | |
|---|---|
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 168.04 g/mol [1] |
| Appearance | Liquid [1] |
| Odor | Slight non-pungent odor [1] |
| Density | 1.44 [1] |
| Boiling point | 22.8 °C [1] |
| Solubility | Negligible [1] |
| Predicted LogP | 2.6 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C3H2F6O |
| IUPAC name | 2-(difluoromethoxy)-1,1,1,2-tetrafluoroethane |
| SMILES | C(C(F)(F)F)(OC(F)F)F |
| InChI | InChI=1S/C3H2F6O/c4-1(3(7,8)9)10-2(5)6/h1-2H |
| InChIKey | DPYMFVXJLLWWEU-UHFFFAOYSA-N |
| CAS number | 57041-67-5 |
| UNII | CRS35BZ94Q |
| PubChem CID | 42113 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | Elimination dependent on minute ventilation |
| Metabolism | Minimally metabolized |
| Routes of administration | Inhalation |
| Toxicity [] | |
|---|---|
| LD50 | Swiss Rate: - i.v: 312.0 mg.kg-1 [1] |
Desflurane (also known as Suprane, Desflurano, difluoromethyl 1,2,2,2-tetrafluoroethyl ether, Desfluranum, I-653, I 653, (+-)-2-Difluoromethyl 1,2,2,2-tetrafluoroethyl ether, 1,1,1,2-tetrafluoro-2-(difluoromethoxy)ethane, Ethane, 2-(difluoromethoxy)-1,1,1,2-tetrafluoro- or Ethane, 2-(difluoromethoxy)-1,1,1,2-tetrafluoro-, (+-)-) is a substance of the ether class.
Chemistry
Stereochemistry []
Desflurane is a racemic mixture of the enantiomers (optical activity ( + / - )).
| Stereoisomerism |
|---|
| Stereoisomers from PubChem |
Druglikeness
Lipinski's rule of five
Desflurane matches Lipinski's rule of five.Pharmacology
ATC Classification
- nervous system (N)
- anesthetics (N01)
- anesthetics, general (N01A)
- halogenated hydrocarbons (N01AB)
- (N01AB07)
- desflurane (N01AB07)
MeSH Classification
- anesthetics, inhalation (M0027998)
Mechanism of action []
The mechanism of inhalational anesthetics is still not fully understood. They can block excitatory ion channels and increase the activity of inhibitory ion channels. The most notable agonism is at the GABA<sub>A</sub> channel. Desflurane is also an agonist of glycine receptors, antagonist of glutamate receptors, inducer of potassium voltage gated channels, and inhibits both NADH-ubiquinone oxioreductase chain 1 and calcium transporting ATPases. An older school of thought is the unitary theory of general anesthetic action, suggesting that desflurane affects the lipid bilayer of cells. Studies of other halogenated inhalational anesthetics have shown that the lipid bilayer spreads out more thinly as the anesthetic incorporates into the bilayer. However, the anesthetic does not bind to lipid heads or acyl chains of hydrocarbons in the bilayer. The effect of incorporating into the lipid bilayer is not well described. By incorporating into the lipid bilayer, anesthetics may introduce disorder in the lipids, leading to some indirect effect on ion channels. However, this theory remains controversial. [1]
Medical side effects []
124 side effects listed on drug labels in SIDER 4.1 (desflurane).
- Nausea
- Breath holding
- Breath holding attack
- Cough
- Vomiting
- Laryngospasm
- Apnoea
- Tachycardia
- Bradycardia
- Hypertension
- Conjunctival hyperaemia
- Headache
- Pharyngitis
- Arrhythmia
- Asthma
- Nodal arrhythmia
- Salivary hypersecretion
- Abdominal pain
- Gastrointestinal pain
- Pancreatitis acute
- Asthenia
- Fatigue
- Atrial fibrillation
- Coagulopathy
- Bone disorder
- Bronchospasm
- Cholestasis
- Ulcerative keratitis
- Dizziness
- Eye burns
- Eye disorder
- Body temperature increased
- Gastrointestinal disorder
- Cardiac arrest
- Cardiac disorder
- Haemoptysis
- Haemorrhage
- Haemoglobin
- Hepatitis
- Cytolytic hepatitis
- Hyperkalaemia
- Malignant hypertension
- Hypokalaemia
- Hypotension
- Jaundice
- Liver disorder
- Hepatocellular injury
- Foetor hepaticus
- Mediastinal disorder
- Myocardial infarction
- Acute coronary syndrome
- Nervous system disorder
- Palpitations
- Pruritus
- Rhabdomyolysis
- Convulsion
- Shock
- Torsade de pointes
- Erythema
- Urticaria
- Angiopathy
- Tachyarrhythmia
- Encephalopathy
- Hepatic failure
- Hepatic function abnormal
- Migraine
- Hepatic necrosis
- Eye pain
- Aspartate aminotransferase increased
- Alanine aminotransferase increased
- Blindness transient
- Endophthalmitis
- Ocular hyperaemia
- Respiratory arrest
- Malnutrition
- Metabolic acidosis
- Malaise
- Discomfort
- Feeling abnormal
- Ill-defined disorder
- Myalgia
- Musculoskeletal discomfort
- Visual acuity reduced
- Eye irritation
- Skin burning sensation
- Hepatobiliary disease
- Blood bilirubin increased
- Respiratory distress
- Electrocardiogram T wave inversion
- Ammonia increased
- Ventricular failure
- Electrocardiogram ST-T change
- Ventricular hypokinesia
- Ocular icterus
- Respiratory failure
- Coagulation test abnormal
- Drug administration error
- Mental disorder
- Infection
- Conjunctivitis
- Cyanosis
- Dyspnoea
- Hypercapnia
- Carbon dioxide increased
- Keratitis
- Muscle rigidity
- Renal failure
- Vasodilation procedure
- Agitation
- Blood creatinine increased
- Myocardial ischaemia
- Liver function test abnormal
- Tachypnoea
- Respiratory depression
- Pulmonary function test decreased
- Hypoxia
- Ventricular extrasystoles
- Extrasystoles
- Transaminases increased
- Light anaesthesia
- Electrocardiogram abnormal
- Fluid overload
- Oxygen saturation decreased
- Infestation
Indications
- Apnoea
- Cough
Legal status []
- Australia: Desflurane is a Schedule 4.
- Brazil: Desflurane is a C1.[3]
- United States: Desflurane is Prescription only.
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 42113, Desflurane. Accessed November 22, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/42113
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Desflurane. UNII: CRS35BZ94Q. Global Substance Registration System. Accessed November 22, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/CRS35BZ94Q
Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 31 March 2023. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 08:20:17 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 08:20:13 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 08:20:13 |
| gsrs | ok | 2026-11-20 08:20:13 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0015320) | 2026-11-20 08:20:13 |
| kegg | ok | 2026-11-20 08:20:16 |
| pubchem | ok | 2026-11-20 08:20:12 |
| missing (no r/tripreports posts mention it) | 2026-11-20 08:20:13 | |
| sider | ok | 2026-11-20 08:20:13 |
| structure | ok | 2026-11-20 08:20:13 |
| wikipedia | ok | 2026-11-20 08:20:13 |